JUBILANT PHARMOVA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 700.7 INR | +4.30% |
|
+9.90% | +28.46% |
| Apr. 17 | Jubilant Pharmova Unit Gets VAI Status for Roorkee, India Facility | MT |
| Feb. 02 | India's Jubilant Pharmova posts quarterly profit | RE |
| Sales 2022 | 61.3B 734M | Sales 2023 | 62.82B 752M | Capitalization | 44.42B 532M |
|---|---|---|---|---|---|
| Net income 2022 | 4.14B 49.54M | Net income 2023 | -610M -7.3M | EV / Sales 2022 | 1.37 x |
| Net Debt 2022 | 22.03B 264M | Net Debt 2023 | 26.44B 317M | EV / Sales 2023 | 1.13 x |
| P/E ratio 2022 |
14.9
x | P/E ratio 2023 |
-72.8
x | Employees | 5,778 |
| Yield 2022 |
1.29% | Yield 2023 |
1.79% | Free-Float | 36.33% |
More Fundamentals
* Assessed data
More news
| 1 day | +4.30% | ||
| 1 week | +9.90% | ||
| Current month | +22.95% | ||
| 1 month | +22.75% | ||
| 3 months | +26.32% | ||
| 6 months | +71.11% | ||
| Current year | +28.46% |
1 week
607.55
724.40
1 month
558.75724.40
Current year
532.15724.40
1 year
299.05724.40
3 years
268.90925.00
5 years
234.351 046.95
10 years
115.601 046.95
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 46 | 17-05-22 | |
| Chief Executive Officer | 37 | 17-05-22 | |
Arvind Chokhany
DFI | Director of Finance/CFO | 52 | 21-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 67 | 81-12-31 | |
| Chairman | 71 | 78-06-20 | |
| Chief Executive Officer | 46 | 17-05-22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 700.7 | +4.30% | 2 364 472 |
| 24-04-16 | 671.8 | +3.23% | 796,703 |
| 24-04-15 | 650.8 | +2.07% | 583,107 |
| 24-04-12 | 637.6 | -1.81% | 247,603 |
| 24-04-10 | 649.4 | -0.17% | 239,824 |
Delayed Quote NSE India S.E., April 18, 2024 at 07:43 am EDT
More quotes
Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Company's segments include Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs. The Pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six manufacturing facilities in India, United States and Canada and a network of approximately 48 radio pharmacies in the United States. The Contract Research and Development Services segment provides drug discovery and development services as well as clinical data software and service solutions. The Proprietary Novel Drugs segment is a patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.
Sector
Pharmaceuticals
Calendar
2024-05-30
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +28.55% | 676B | |
| +23.58% | 554B | |
| -7.64% | 349B | |
| +14.58% | 318B | |
| +7.28% | 291B | |
| +3.02% | 210B | |
| -0.41% | 204B | |
| -10.02% | 194B | |
| -12.07% | 144B |
- Stock Market
- Equities
- JUBLPHARMA Stock
- JUBLPHARMA Stock
